A study to evaluate the effectiveness of HMB-002 as a prophylactic treatment option to prevent and reduce the frequency of bleeding events in participants with Von Willebrand Disease.
Study Details
Internal Title:
Hemab - HMB-002-102 (Velora Pioneer)
PCH IRB Number:
IRB-26-012
Clinical Trials Government Identifier:
NCT06754852
Diagnoses & Treatments:
Von Willebrand Disease, VWD, HMB-002, bleeding events, Velora Pioneer
Study Type:
Clinical Trial
Eligibility:
18 to 65 years old, Type 1, 1C, 2A VWD; minimum annualized treated bleeding event of 3
Enrollment Status:
Open
Phase:
I/II